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Abstract
Management considerations in hypokalemic periodic paralysis include accurate diagnosis, potassium
dosage for acute attacks, choice of diuretic for prophylaxis, identification of triggers, creating a safe
physical environment, peri-operative measures, and issues in pregnancy. A positive genetic test in
the context of symptoms is the gold standard for diagnosis. Potassium chloride is the favored
potassium salt given at 0.5–1.0 mEq/kg for acute attacks. The oral route is favored, but if necessary,
a mannitol solvent can be used for intravenous administration. Avoidance of or potassium
prophylaxis for common triggers, such as rest after exercise, high carbohydrate meals, and sodium,
can prevent attacks. Chronically, acetazolamide, dichlorphenamide, or potassium-sparing diuretics
decrease attack frequency and severity but are of little value acutely. Potassium, water, and a
telephone should always be at a patient's bedside, regardless of the presence of weakness.
Perioperatively, the patient's clinical status sho u l d  b e  c h e c k e d  f r e q u e n t l y .  F i r m  d a t a  o n  t h e
management of periodic paralysis during pregnancy is lacking. Patient support can be found at http:/
/www.periodicparalysis.org.
Introduction
Hypokalemic periodic paralysis is a disorder of muscle
whereby voltage-gated ion channels (typically calcium or
sodium, and less frequently potassium) are mutated,
resulting in abnormalities of sarcolemmal excitation. The
disease typically first manifests in adolescence as bouts of
mild to severe muscle weakness lasting hours and some-
times days associated with hypokalemia triggered most
commonly by rest after exercise or high carbohydrate
meals. Weakness typically recovers when serum potas-
sium normalizes. In some cases, a fixed weakness can
develop, especially in the larger, proximal muscle groups
later in life. Lehmann-Horn et al provide a detailed over-
view of periodic paralysis pathophysiology elsewhere [1].
Being Medical Director of the Periodic Paralysis Associa-
tion and myself a carrier of the R672S mutation in Nav1.4,
encoded by SCN4A (my case was reported by Venance et
al [2]), has allowed me to compare the experiences of
scores of patients who suffer from muscle ion chan-
nelopathies. Through my own experience with primary
hypokalemic periodic paralysis, as well as through numer-
ous anecdotes of other sufferers, I have collected some
useful insights in dealing with the disorder on a day to day
basis. To verify each of these management strategies in a
scientifically rigorous way is important but impractical
due to the rarity of the periodic paralyses. As such, a good
portion of this manuscript represents my personal obser-
vations in the management of hypokalemic periodic
paralysis.
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Discussion
Potassium dosing and indications
While one could make a physiologic argument for one or
another type of potassium salt, in all likelihood, the coun-
ter ion is unimportant. It is felt that potassium chloride is
best absorbed [3], making this the favored salt in an acute
attack. Also, metabolic alkalosis frequently accompanies
hypokalemia and Cl- best corrects the alkalosis [4]. That
being said, each vehicle – be it oral solution, powder dis-
solved in water, or sustained release tablet – has its place
in management. Oral solution, as measured in mg/mL,
can be as effective as powder in water; however, it is cum-
bersome to convert milligram (mg) dose to mEq dose,
and confusion can arise because of this. Indeed, depend-
ing on the counter ion, one mg of potassium salt can
translate into different mEq amounts. To be safe and con-
sistent, always dose in milliequivalents (mEq). Table 1 is use-
ful for conversion to mEq. Various brands contain
combinations of salts, and in these cases, it is critical to
read the package insert if dosing on a mg basis rather than
a mEq basis.
With respect to liquid/aqueous versus sustained release
tablet, liquid and aqueous forms of potassium are useful
prior to performing known triggers, such as eating a high
carbohydrate load and vigorous activity or at the start of
an episode of weakness. (Once the vigorous activity is
over and rest begins, an attack will often occur without
appropriate prophylaxis). In cases where the patient has
frequent early morning attacks, a trial of sustained release
potassium tablets taken at time of sleep may be war-
ranted. Some may also find it necessary to take sustained
release tablets once or twice daily as a standing regimen in
combination with immediate release potassium as
needed. The downside to chronic potassium administra-
tion, especially with the use of sustained release tablets, is
gastric irritation from locally high potassium salt concen-
trations. This problem is often well-controlled with a pro-
ton pump inhibitor.
The vehicle in which to mix the potassium salt warrants
consideration. Water is the favored option. Sports drinks,
such as Gatorade®, may at first blush seem intuitively ben-
eficial as they contain "electrolytes" and "potassium";
however, they contain high sugar loads and often high
sodium content, both of which can trigger attacks in
hypokalemic periodic paralysis patients. Potassium
should be taken with ample volumes of water, for exam-
ple, at least 120 mL (about 4 oz) of water per 20 mEq [3].
I have found that dissolving the potassium in the least
amount of liquid possible, ingesting in one shot, and fol-
lowing with an 8–12 oz water chaser is more tolerable
than drinking a full 8–12 oz of aqueous solution.
Potassium can be given orally for attack prophylaxis.
Assuming normal renal function, most patients are
grossly under-dosed. One can find the appropriate dose
by trial and error, or approach it more scientifically. Either
way is acceptable. The scientific approach involves meas-
uring serum potassium 20 to 40 minutes after fixed oral
potassium loads on separate days. This should provide
some confidence to both patient and physician as to what
is safe and what may be dangerous. For example, it is not
uncommon for a 60 kg individual to require 60 mEq of
potassium for attack prophylaxis prior to vigorous exer-
cise. Using an aqueous form (rather than sustained-
release tablets) allows for an appropriate peak in serum
potassium concentration and should be taken no more
than one hour prior to exercise. Trial and error will allow
the individual patient to find his appropriate therapeutic
window with respect to dose and timing of dose. It is pru-
dent to try different doses prior to exercise, starting low
and titrating up prior to each exercise session until the
minimum dose that prevents paralysis is found. Repeated
periods of exercise spaced as little as three hours apart may
require additional prophylaxis. For example, one may
need an additional 60% of the first dose taken that day.
The danger of overdosing on oral potassium is low [3],
provided that the dose is within reason. A good rule of
thumb is not to exceed 100 mEq in a day in the absence
of an attack. Renal excretion of potassium is 90% and
fecal excretion is 10%. Renal excretion becomes more
robust with chronic potassium dosing [3]. Before cardiac
side effects would occur, osmotic diarrhea and paresthesia
of the lips, hands, and feet typically intervene. This would
Table 1: Potassium salts and their milligram to milliequivalent (or millimole) relationships [2]
Spoken name Chemical Formula mg mEq K+ (or mM K+)
Elemental potassium ion K+ 39.1 1
Potassium chloride (powder or tablets) KCl 1500 20
Potassium bicarbonate (powder, tablets, or self-dissolving tablets) KHCO3 650 6.5
Potassium citrate monohydrate K3C6H5O7*H2O 540 15 (i.e 5 mEq of K3C6H5O7)
Potassium chloride 10% oral solution, 15 mL KCl 10% oral solution 1500 20
Potassium chloride 20% oral solution, 15 mL KCl 20% oral solution 3000 40
Potassium gluconate elixer, 15 mL KC6H11O7 4680 20
Potassium gluconate tablets KC6H11O7 500 2Journal of Translational Medicine 2008, 6:18 http://www.translational-medicine.com/content/6/1/18
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be an indication to limit the potassium intake. Patients
should be educated as to the safe and appropriate use of
their potassium; however, they should never be restricted
as to the amount of potassium supplement available to
them. One month's prescription should be able to accom-
modate the assumption that the patient will use their
maximum daily dosage each day of that month.
Oral potassium administration, assuming normal renal
function, is the mainstay for treating attacks of hypokale-
mic paralysis. Here too, most patients are grossly under-
dosed with respect to potassium supplementation during
an attack. Large bolus doses are favored over smaller,
spaced out, incremental doses. As a general rule, 40 to 60
mEq K+ raises plasma potassium concentration by 1.0 to
1.5 mEq/L, and 135 to 160 mEq K+ raises plasma potas-
sium by 2.5 to 3.5 mEq/L [4]. For a 60 to 120 kg man, 60
mEq is a reasonable initial dose (i.e. 0.5 – 1 mEq/kg).
Arriving at the optimal dose for any one individual will
initially be a process of trial and error. For example, some
patients find that 0.5 mEq K+/kg reproducibly resolves
attacks, and others find they need 1 mEq K+/kg. Of course,
the dose will vary from attack to attack depending on the
severity of its associated hypokalemia. Unfortunately,
patients usually do not have the benefit of a serum potas-
sium reading when faced with the decision of what dose
to take.
Quicker results are obtained using aqueous potassium,
and this is the favored form for acute attacks. Partial, if not
complete, response should be seen within 30 minutes. If
no improvement is seen after 30 minutes, an additional
30% dose should be given – that is, an additional 0.3
mEq/kg. This process should proceed up to roughly 100
mEq. If an attack has not resolved after 100 mEq of potas-
sium, it is prudent to monitor the serum potassium prior
to further supplementation in an acute care setting. Typi-
cally, the total dose of potassium should not exceed 200
mEq in a 24 hr period in the treatment of an acute attack.
Intravenous potassium should be avoided whenever pos-
sible; however, it is indicated for arrhythmia due to
hypokalemia or airway compromise due to ictal dys-
phagia or accessory respiratory muscle paralysis. Mannitol
(which is inert) should be used as the solvent (rather than
saline or dextrose, which are both potential triggers of
attacks) [5]. One must be cautious to give only 10 mEq at
a time, separated by anywhere from 20–60 minutes, as
there is a distinct danger of overshooting the mark, result-
ing in hyperkalemia. That is, the first aim is to get the
patient out of danger rather than attempting rapid, com-
plete correction [4]. Patience, provided that the patient is
stable, is important. While 10 mEq per hour is the favored
rate [4], urgent situations such as severe arrhythmia or res-
piratory compromise may warrant temporary, higher rates
of administration [3]. The hypokalemia in hypokalemic
periodic paralysis is due to potassium shifts from blood to
muscle. When the attack resolves, potassium returns to
the blood. So, the idea is to administer just enough potas-
sium to induce physiologic resolution of the attack.
Patients will often complain of a burning sensation due to
potassium irritation of the recipient vein. There are anec-
dotal reports of intravenous lidocaine being used to miti-
gate the burning; however, the safety of this strategy has
not been established. If larger doses than 10 mEq at one
time are needed, a larger vein should be used, sometimes
requiring a femoral venous line [4]. Furthermore, no
more than 80 mEq per liter, and preferably no more than
40 mEq per liter, should be used, even in a central vein
[4,5].
Maintenance therapy
While potassium can be taken chronically as mainte-
nance, the favored approach is to add one of a variety of
diuretics, some of whose mechanisms in periodic paraly-
sis are poorly understood. Diuretics are not helpful for acute
attacks. Their role is to decrease the frequency and severity
of attacks over time. The first line approach is acetazola-
mide, dosed anywhere from 125 mg to 1000 mg per day
in divided doses, either in immediate or sustained release
preparations [6]. Finding the correct dose requires some
trial and error, with 250 mg twice daily being a reasonable
starting point. Some patients have worsening of the para-
lytic attacks with acetazolamide. Others complain of par-
esthesias and cognitive impairment (described by patients
as mental dullness, fogginess, inability to concentrate, or
confusion) from acetazolamide. Acetazolamide-induced
nephrolithiasis (calcium phosphate stones) is not uncom-
mon [7,8] and can often be controlled with dose reduc-
tion and appropriate hydration under consultation with a
urologist.
Because carbonic anhydrase inhibitors are potassium-
wasting, occasional potassium supplementation, even in
the absence of an attack, may be warranted. If symptoms
worsen with acetazolamide, they likely will not improve
with dichlorphenamide. However, if the patient has no
response with acetazolamide or if symptoms were once
controlled with acetazolamide but progress to become
refractory to acetazolamide, then dichlorphenamide is a
good option. Dichlorphenamide is also a reasonable first-
line therapy; however, it is more potent than acetazola-
mide and issues with mental confusion and cognitive
impairment tend to be more frequent than with acetazola-
mide [6]. Dosing is based on the premise that dichlo-
rphenamide is five times as potent as acetazolamide, such
that a 250 mg dose of acetazolamide corresponds to a 50
mg dose of dichlorphenamide [6].Journal of Translational Medicine 2008, 6:18 http://www.translational-medicine.com/content/6/1/18
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If carbonic anhydrase inhibitors are not an option, aldos-
terone antagonists can be useful. Specifically, spironolac-
tone is commonly used with good success since it is a
potassium-sparing diuretic. Side effects of gynecomastia
make this a less favored treatment for males. Epleronone
is a novel aldosterone antagonist that reportedly has fewer
issues with gynecomastia while retaining its potassium-
sparing properties. It is also FDA Pregnancy Category B. As
such, this should be tried before spironolactone. It is safe
to take potassium supplementation and be on an aldos-
terone antagonist in the case of hypokalemic periodic
paralysis. However, the patient and physician must work
together to find the minimum amount of potassium
required while on the aldosterone antagonist to prevent
or abort an attack without causing hyperkalemia. Blood
pressure should be monitored when making dose adjust-
ments.
When one agent or another agent does not adequately
control the frequency and/or severity of attacks, combina-
tion therapy of a carbonic anhydrase inhibitor (provided
it does not cause disease exacerbation) and an aldosterone
antagonist may be tried. Other less frequently used potas-
sium-sparing diuretics that can also be tried are triam-
terene and amiloride. Electrolytes should be monitored
initially every two weeks, and monthly or quarterly there-
after.
Behavioral and environmental management, trigger 
identification, and diet
A safe bedside environment must be established for the
periodic paralysis patient. Frequently, a patient will awake
during the early morning with enough movement to self-
medicate and call for help before progressing to complete
paralysis. If the patient is fortunate enough to still have
movement, he must: a) call for help and alert someone
that he is paralyzed, and b) immediately take his potas-
sium prior to further activity. This requires the following
at the bedside: a telephone, a plastic bottle of water that is
easily opened, potassium, a plastic or paper cup in which
to mix the medicine, and a spoon and/or straw to mix the
medicine. Glass should not be kept at the bedside because
patients have lack of coordination and strength due to
paralysis and risk dropping and breaking the glass. There
should be no slippery rugs at the foot of the bed, as
patients sometimes need to maneuver in a partially para-
lyzed state and cannot balance themselves in the event of
lost traction. Many patients have suffered bone fractures
from falling while paralyzed. Finally, the bed should not
be near an air conditioning vent in the summer or near a
window during winter, as cold during the night can
induce an attack, either as a trigger unto itself or by induc-
ing shivering, which constitutes exercise that results in an
attack.
The time from premonitory symptoms to full blown
attack is often very short, on the order of minutes. For that
reason, a sufficient dose of potassium to prevent and
relieve an attack should be kept in various places at all
times, including: at the bedside, in a pocket of coat, in the
car, in the pocketbook, and in the suitcase. Potassium
should be kept on the person at all times.
One helpful exercise, especially for those individuals
experiencing a high frequency of attacks, is to make a
diary of attacks. They should document whenever they get
an attack, paying attention to what they ate within the 24
to 36 hours preceding an attack, what activities they did
within the preceding 24–36 hours prior to the attack, and
what medications they took or forgot to take. As some
triggers are completely individual, they are only identified
by careful attention to the details surrounding the attacks.
Once triggers are identified, the patient should avoid
them. Sometimes one can relate a series of attacks over
consecutive days to one large triggering event.
Identifying and avoiding triggers of attacks is imperative.
Numerous triggers have been reported to induce attacks of
paralysis. The most consistent are rest after exercise and
high carbohydrate meals. A high carbohydrate meal
causes a spike of endogenous insulin release, resulting in
a potassium shift from outside to inside myocytes. The
potassium shift triggers inappropriate activity of mutated
voltage-gated ion channels, resulting in membrane depo-
larization, and manifesting as paralysis.
Sodium intake triggers some, but not all, patients. It is
important for salt-sensitive patients to discover the
amount of salt that induces attacks for them. This amount
varies from person to person, and indeed, from day to
day. Patients must be aware of the amount of salt in the
foods they eat, preferably prior to eating them. For those
patients that like to salt their food, potassium chloride
(available as NoSalt®), rather than sodium chloride, can
be used.
The remaining list of triggers vary for individual patients,
but patients and doctors should be aware of what types of
things to look out for: cold, upper respiratory infections
(both viral and bacterial), fever, lack of sleep/fatigue, Chi-
nese food – with or without monosodium glutamate (pre-
sumably a trigger because of high starch content), alcohol,
dehydration, startle, any medications – some with a phys-
iological explanation (insulin, beta-agonists, corticoster-
oids [9]) and many without (determined by trial and
error), menstrual cycle, change in humidity or barometric
pressure, and change in daily activity patterns (i.e., going
from regular exercise one week to being sedentary the next
week and vice versa).Journal of Translational Medicine 2008, 6:18 http://www.translational-medicine.com/content/6/1/18
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Patients are sometimes unclear as to what constitutes a
"high carbohydrate food," and these must be outlined
explicitly to the patient. One woman got paralyzed from
"coffee" but did not equate the three teaspoons of sugar
she added with the paralysis trigger. Pastas, candy bars,
sports and energy drinks, cola drinks, orange juice, apple
juice, pizza, bread, rice, potatoes, and beer (aside from
alcohol content) are all sources of high carbohydrates.
Some people have had success with buckwheat and other
sources of more complex carbohydrates.
A common misconception is that one can increase banana
intake to avoid paralysis. A medium-sized (118 g, 7 1/2
inch-long) banana contains 467 mg of potassium, or 12
mEq of potassium (not all of which would be bioavaila-
ble), and 28 g carbohydrates [10]. One would need to eat
six bananas to get 72 mEq of potassium, which is a signif-
icant (168 g) carbohydrate load and constitutes roughly
1.5 lbs. worth of bananas!
Intercurrent illness, surgery, and pregnancy
Diarrhea is potassium-wasting, and can precipitate attacks
of paralysis. Some patients are challenged when the
diarrhea is a result of too much oral potassium intake over
a short period of time. In this case, further supplementa-
tion should probably not be done without monitoring of
serum potassium. Influenza can cause some people to be
particularly susceptible to attacks; that is, for a given trig-
ger, the threshold of attack is lower during an upper respi-
ratory infection than during health. Insulin-dependent
diabetes mellitus is a particular challenge, in that insulin
drives potassium into cells, precipitating hypokalemia
and an attack of paralysis. Indeed, insulin can be used as
a diagnostic challenge test; however, the glucose-insulin
challenge test is discouraged due to risk of both profound
paralysis and life-threatening hypoglycemia.
Periodic paralysis patients have special needs with respect
to both minor and major surgery. The gene, CACN1AS, in
which mutations cause primary hypokalemic periodic
paralysis, is allelic to that which causes malignant hyper-
thermia susceptibility [11]. Malignant hyperthermia is
characterized by generalized muscle rigidity, rhabdomyol-
ysis with elevated creatine kinase, hypercarbia, acidosis,
hyperkalemia, and hyperthermia after exposure to inhala-
tion narcotics or depolarizing muscle relaxants [12].
Genetic linkage of malignant hyperthermia and hypokale-
mic periodic paralysis has never been definitively demon-
strated [13]; however, surgeons and anesthesiologists
should be aware of this possibility and be prepared to deal
with it. More often, patients will simply become paralyzed
during or after surgeries, as the surgical theater is cold, the
surgery itself is a stressor, and the use of triggering agents
(i.e., dextrose and saline) is often unavoidable. Difficulty
with extubation can theoretically be due to an attack of
paralysis. As such, it is prudent to monitor potassium
somewhat more carefully in the peri-surgical period as
well as to check on the patient frequently. Another possi-
bility, albeit unlikely, is inadequate anesthesia during sur-
gery, whereby paralysis from an attack rather than from
pharmacologic neuromuscular blockade is mistaken for
successful anesthesia. With respect to minor surgeries or
procedures in the primary care, dermatology, ophthal-
mology, or dental settings, intralesional lidocaine with
epinephrine or beta-agonist eye drops can cause sudden
and severe attacks of paralysis in some individuals. If this
is a known complication, measures to avoid these agents
should be taken where possible. For example, one can use
lidocaine without epinephrine. One opthalmologist suc-
cessfully employed lacrimal duct plugs to avoid absorp-
tion of dilating eye drops.
Management of periodic paralysis during pregnancy and
during parturition is challenging. Potassium management
should be no different from prior to pregnancy. Carbonic
anhydrase inhibitors like acetazolamide and dichlorphen-
amide are FDA Pregnancy Category C. Their use must be
weighed against the risk of not taking them. Many women
choose to avoid carbonic anhydrase inhibitors for the
duration of their pregnancy. For some, this is tolerable, for
others, it is exceedingly challenging. Of note, eplerenone
is FDA Pregnancy Category B and is the favored option for
those patients who cannot manage on potassium supple-
mentation alone.
Diagnosis
Accurately diagnosing channelopathies is difficult to the
uninitiated (and to the initiated!). Aside from the classical
periodic episodes of weakness in response to triggers,
patients often report additional symptoms either before,
during, or after attacks that may not have good physio-
logic explanations. These include prodromal paresthesias,
sweating [12], post-ictal myalgia [14], post-ictal extreme
fatigue, thirst, shortness of breath (either due to anxiety or
to the episode itself), palpitations, clumsiness, irritability,
and mental dullness. The physical exam is often normal.
The neurological strength exam itself can trigger an epi-
sode, and some patients have reported leaving a doctor's
office very weak from the sudden, unexpected muscle
work of the exam.
The list of differential diagnoses (Table 2) stems from
three basic considerations: a) exercise-induced symptoms
of either stiffness or weakness, b) recurrent bouts of
hypokalemia, and c) episodic muscle weakness. The pres-
ence of the following disorders does not exclude, can
coexist with, and should NOT preclude treatment of peri-
odic paralysis, when present, and vice versa: chronic
fatigue syndrome, fibromyalgia, depression, personality
disorder, psychosomatization, and malingering (oftenJournal of Translational Medicine 2008, 6:18 http://www.translational-medicine.com/content/6/1/18
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NOT the case, but a diagnosis that is all too frequently and
inappropriately given). In the absence of readily available
genetic testing or dangerous provocative testing, the diag-
nosis often can be identified with a judicious combina-
tion of considerations (Table 3).
Provocative testing can be dangerous and is not a favored
first-line method of diagnosis. Potassium challenge tests
risk hyperkalemic arrhythmia, even in an acute care set-
ting. Insulin challenge tests can be equally dangerous due
to risk of hypoglycemia. Simple exercise challenge, which
is relatively safe, is partly helpful when the ictal serum
potassium is high or low. The distinction of hyperKPP ver-
sus hypoKPP can often be made, but the presence of ATS
would still be unresolved. In fact, hyperkalemic and
hypokalemic challenges should never be done if there is a
Table 2: Differential Diagnosis of Channelopathies
Thyrotoxic hypokalemic periodic paralysis (TPP)
Primary (or familial) hypokalemic periodic paralysis (hypoPP)
Hyperkalemic periodic paralysis (hyperPP)
Paramyotonia congenita (PMC)
Potassium-aggravated myotonia (PAM) [22, 23] (includes myotonia fluctuans [24], acetazolamide-responsive myotonia [25], and myotonia 
permanens [26])
Myotonia congenita, both recessive and dominant (MC)
Andersen-Tawil syndrome (ATS) (formerly Andersen syndrome)
Hyperaldosteronism and physiologically similar states
Renal tubular acidosis Type IV (RTA)
Diuretic abuse
Myasthenia gravis
Table 3: Some Historical, Physical Exam, and Laboratory Diagnostic Considerations for Ion Channelopathies [9,16]
Question If positive, suggests:
Family history hyperPP, hypoPP, ATS, PMC, MC, PAM
Carbohydrates induce attacks TPP, hypoPP, +/- PMC, ATS
Carbohydrates ameliorate attacks hyperPP, ATS, PMC, PAM
Stiffness after exercise PMC, MC
Tongue stiffens when eating ice cream PMC
Less stiffness decreases with repeated exercise of a given muscle (warm-
up phenomenon)
MC
Myotonia increases with continued exercise PMC
Serum potassium elevated during attack PAM, hyperPP, ATS, PMC
Serum potassium normal during attack all diagnoses are possible
Serum potassium low during attack hypoPP, TPP, ATS, PMC, diuretic abuse, hyperaldosterone states, RTA
Difficult to open eyes in the cold PMC
Attacks of muscle stiffness MC, ATS, PMC, PAM
Attacks of muscle weakness MC, TPP, hyperPP, hypoPP, ATS, PMC
Duration of attacks are hours hypoPP, TPP, ATS, PMC
Duration of attacks are minutes to hours hyperPP, PAM, MC, ATS
EMG with myotonia hyperPP, PAM, MC
EMG silent during attack of weakness hypoPP, TPP, ATS, PMC, MC
Palpitations ATS, hypoPP, hyperPP, TPP, PMC
EKG – tachycardia TPP
EKG – long QTc and/or ventricular arrhythmia ATS
EKG – u waves ATS, hypoPP, TPP
Hyporeflexia during attack of weakness hypoPP, TPP, ATS, hyperPP
Percussion myotonia MC, PMC, PAM
Physical exam with some of: fifth digit clinodactyly, ocular hypertelorism, 
low-set ears, webbed fingers/toes, broad nasal root, small mandible, short 
stature, brachydactyly, microcephaly, short palpebral fissures, thin upper 
lip, small hands/feet, residual primary dentition, delayed bone age [16]
ATS
McManis nerve conduction protocol (i.e., changes in compound muscle 
action potential after exercise)
ATS, hyperPP, hypoPP, TPP
Muscle biopsy with tubular aggregates ATS, hyperPP, hypoPP, TPP, PMC, PAM, MC
hyperPP = hyperkalemic periodic paralysis; hypoPP = hypokalemic periodic paralysis; ATS = Andersen-Tawil syndrome; PMC = paramyotonia 
congenita; MC = myotonia congenita; PAM = potassium-aggravated myotonia; TPP = thyrotoxic periodic paralysis; RTA = renal tubular acidosisJournal of Translational Medicine 2008, 6:18 http://www.translational-medicine.com/content/6/1/18
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suspicion of ATS. Also, an equivocal challenge test does
not rule out one or another disorder.
Both hyperkalemic and hypokalemic periodic paralysis
can present with normokalemia during attacks. Potassium
challenge in hyperkalemic periodic paralysis would
induce an attack. Potassium administration in hypokale-
mic periodic paralysis makes the attack resolve. Further-
more, it is helpful in some cases to compare the ictal
potassium with the patient's baseline. Sometimes both
ictal and baseline are within normal limits but ictal is
either lower or higher than baseline, rendering a clue as to
the nature of the periodic paralysis.
Various laboratory examinations (outside of ictal and
interictal serum potassium measures) play an important
role in both diagnosis and management of hypokalemic
periodic paralysis. Specifically, EKG, TSH, free T3, and free
T4 are the minimum indicated labs, with renal and adre-
nal function also recommended. Thyroid function evalu-
ation will identify thyrotoxic periodic paralysis, which
should resolve with the achievement of euthyroid status.
Renal and adrenal axis screening is helpful to rule out
hyperaldosterone states, renal tubular acidosis type IV,
and diuretic abuse. Perhaps most important is the EKG, as
patients with ATS typically have a long QTc interval (that
is frequently overlooked or dismissed) and/or a variety of
ventricular arrhythmias, including polymorphic ventricu-
lar tachycardia, bidirectional ventricular tachycardia, and
ventricular bigeminy. One patient with Wolff-Parkinson
White symdrome and primary hypokalemic periodic
paralysis has been reported [15], but this is likely a coin-
cidental association. Taking an EKG both during asympto-
matic periods with normal serum potassium and during
an attack (when potassium levels are low) is considered
standard of care. Oftentimes, arrhythmias in this disorder
are uncovered during the attack; whether or not they
require treatment is a difficult judgement call.
The role of genetic testing is becoming increasingly impor-
tant for cases with a high pretest probability of being a
neuromuscular ion channelopathy. Not only can genetic
testing reliably distinguish hyperPP from hypoPP and
ordinary periodic paralysis from ATS, it also has some
bearing on prognosis. For example, patients with hypoPP
related to sodium channel mutations have not demon-
strated permanent muscle weakness (PMW) whereas
those patients with calcium-channel related mutations are
at greater risk for PMW [16]. To date, other clinically use-
ful genotype-phenotype correlations are lacking [16,17].
Genetic testing has very high specificity but poor sensitiv-
ity. A negative genetic test does not rule out the presence
of periodic paralysis, as there are believed to be other, as
yet unidentified, mutations and channels that are respon-
sible for the clinical manifestations of these disorders. A
positive test, on the other hand, is confirmatory and
extremely informative. Genetic testing is available on a
research basis in various centers around the world.
With respect to genetic counseling, these disorders are
autosomal dominant with decreased penetrance in some
females. The predeliction for Asian males relates only to
the acquired, thyrotoxic form of hypokalemic periodic
paralysis. Nearly all patients with periodic paralysis live
long, productive, and fulfilling lives.
Patient support
There are several patient support organizations for peri-
odic paralysis patients. The most relevant are the Periodic
Paralysis Association (PPA), the Periodic Paralysis News
Desk, and the Muscular Dystrophy Association (their web
addresses can be found in the References section below)
[18-20]. The PPA is a non-profit charitable corporation
founded in recognition of the need for an organization
that fosters awareness of the periodic paralyses, promotes
science-based information regarding this class of disorder,
and champions the interests of the Periodic Paralysis
Community. The Periodic Paralysis News Desk provides
information on the periodic paralyses for patients, their
families and caregivers, and physicians. Importantly, this
website is available in Spanish. Both organizations con-
tain listservs for patients to share their experiences with all
aspects of this and other neuromuscular ion channelopa-
thies. The PPA has created an on-line patient registry [21],
whose aim is to aid in periodic paralysis-related research.
Conclusion
A myriad of questions surrounding management of this
condition remains unstudied. Of particular significance
are: 1) What percent of patients will go on to permanent
muscle weakness, and are there markers for this risk? 2) Is
permanent muscle weakness preventable? 3) Does strict
control of attacks influence development of permanent
muscle weakness? 4) Are there genotype-phenotype corre-
lations with respect to medication success, triggers,
comorbidities, and disease course? 5) Can patients
develop insensitivity to one or another carbonic anhy-
drase inhibitor over time? 6) Are there risks to chronic
potassium administration? 7) What is the optimal dosing
strategy for potassium during an attack? 8) Does a partic-
ular form of potassium work better than another for this
disease? 9) What is optimal management during preg-
nancy? Studies are needed to validate the diagnostic and
management strategies that are currently in practice. It is
hoped that with the combined efforts of various research-
ers and patient support organizations, a large enough
cohort of genetically characterized patients and families
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thyrotoxic periodic paralysis; RTA: renal tubular acidosis.
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